Sarepta Therapeutics Inc (NASDAQ:SRPT)’s traded shares stood at 0.82 million during the latest session, with the company’s beta value hitting 0.60. At the last check today, the stock’s price was $37.56, to imply a decrease of -0.67% or -$0.25 in intraday trading. The SRPT share’s 52-week high remains $173.25, putting it -361.26% down since that peak but still an impressive 9.21% since price per share fell to its 52-week low of $34.10.
Analysts have given a consensus recommendation of Buy for Sarepta Therapeutics Inc (SRPT), translating to a mean rating of 1.37. Of 17 analyst(s) looking at the stock, 1 analyst(s) give SRPT a Sell rating. 0 of those analysts rate the stock as Overweight while 6 advise Hold as 10 recommend it as a Buy.
Sarepta Therapeutics Inc (NASDAQ:SRPT) trade information
After registering a -0.67% downside in the latest session, Sarepta Therapeutics Inc (SRPT) has traded red over the past five days. The 5-day price performance for the stock is -4.22%, and 3.74% over 30 days. With these gigs, the year-to-date price performance is -69.11%.
The extremes give us $110 and $110 for target low and target high price respectively. As such, SRPT has been trading -192.86% off suggested target high and -192.86% from its likely low.
SRPT Dividends
Sarepta Therapeutics Inc has its next earnings report out in July. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 9.04 million shares, or about 9.5496% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $1.43 billion.
